NASDAQ · Biotechnology

Kardigan, Inc. (KARD) Stock

$21.08 +2.83% NASDAQ: KARD Healthcare

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.

Valuation

MetricValue
Price$21.08
Market Cap$1.88B
P/E Ratio-7.59
P/B Ratio—
P/S Ratio—
EPS (TTM)$-3.01
52-Week High$27.00
52-Week Low$16.25
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio9.41

Latest News

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire · Jun 22, 2026 Kardigan (KARD) Stock Price At $22 Raises Fresh Valuation Questions Simply Wall St. · Jun 21, 2026 Kardigan shares soar after Nasdaq debut Investing.com · Jun 18, 2026 Sector Update: Healthcare Stocks Decline Thursday Afternoon MT Newswires · Jun 18, 2026 Kardigan Announces Pricing of Upsized Initial Public Offering Business Wire · Jun 18, 2026

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held34.97%
Institutions Held33.34%
Institutions Float Held51.26%
Institutional HolderSharesReport Date
Peregrine Capital Management LLC229,7762026-06-30
FNY Investment Advisers, LLC1002026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Kardigan, Inc.

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Kardigan, Inc. is headquartered in US.

Kardigan, Inc. (KARD) stock trades at $21.08 with a market capitalization of $1.88B. The stock is valued at a price-to-earnings (P/E) ratio of -7.59. Over the past 52 weeks the stock has ranged between $16.25 and $27.00, and currently trades 21.9% below its 52-week high.

On profitability, Kardigan, Inc. generates an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.kardigan.bio

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides